Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis | Zendy

Jonathan I. Silverberg | Zendy; Eric L. Simpson | Zendy; Jacob P. Thyssen | Zendy; Melinda Gooderham | Zendy; Gary Chan | Zendy; Claire Feeney | Zendy; Pinaki Biswas | Zendy; Hernán Valdez | Zendy; Marco DiBonaventura | Zendy; Chudy I. Nduaka | Zendy; Ricardo Rojo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

Author(s) -

Jonathan I. Silverberg,

Eric L. Simpson,

Jacob P. Thyssen,

Melinda Gooderham,

Gary Chan,

Claire Feeney,

Pinaki Biswas,

Hernán Valdez,

Marco DiBonaventura,

Chudy I. Nduaka,

Ricardo Rojo

Publication year - 2020

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2020.1406

Subject(s) - medicine , atopic dermatitis , eczema area and severity index , placebo , randomized controlled trial , clinical trial , adverse effect , psychological intervention , pediatrics , physical therapy , dermatology , alternative medicine , pathology , psychiatry

Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research